Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

  • ID: 4013306
  • Report
  • Region: Global
  • 74 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Alnylam Pharmaceuticals
  • Aviragen Therapeutics
  • Gilead Sciences
  • Kyowa Hakko Kirin
  • Mymetics Corporation
  • MORE
About Human Respiratory Syncytial Virus Drugs

Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

Analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

Covered in This Report:
The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.

The Market is Divided into the Following Segments Based on Geography:
- Europe
- ROW
- US

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors:
- AstraZeneca
- AbbVie
- GSK
- Teva Pharmaceutical

Other Prominent Vendors:
- Ablynx
- ADMA Biologics
- Alnylam Pharmaceuticals
- Ark Biosciences
- Aviragen Therapeutics
- Bavarian Nordic
- Boehringer Ingelheim
- Gilead Sciences
- ImmunoVaccine Technologies
- Johnson & Johnson
- Kyowa Hakko Kirin
- Medivir
- Mucosis
- Mymetics Corporation
- Novavax
- Regeneron Pharmaceuticals
- ReViral
- Vaxart

Market Drivers:
- Novel diagnostic tools increase patient population.
- For a full, detailed list, view the full report

Market challenges:
- Continuous change in guidelines from healthcare organizations impacts market growth.
- For a full, detailed list, view the full report

Market Trends:
- Emergence of new entrants likely to change market dynamics.
- For a full, detailed list, view the full report

Key Questions Answered in This Report:
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Alnylam Pharmaceuticals
  • Aviragen Therapeutics
  • Gilead Sciences
  • Kyowa Hakko Kirin
  • Mymetics Corporation
  • MORE
Part 01: Executive summary
  • Highlights
Part 02: Scope of the report
  • Market overview
  • Top-vendor offerings
Part 03: Market research methodology
  • Research methodology
  • Economic indicators
Part 04: Introduction
  • Key market highlights
Part 05: Disease overview
  • Understanding the disease
  • Symptoms
  • Causes
  • Risk factors
  • Complications
  • Tests and diagnosis
  • Key buying criteria
Part 06: Pipeline analysis

Part 07: Market landscape
  • Global respiratory syncytial virus drugs market
  • Five forces analysis
Part 08: Market segmentation by category of drug
  • Approved Drugs
  • Off-label drugs
Part 09: Geographical segmentation
  • Human respiratory syncytial virus drugs market in US
  • Human respiratory syncytial virus drugs market in Europe
  • Human respiratory syncytial virus drugs market in ROW
Part 10: Market drivers
  • Presence of large patient pool fuels market growth
  • Launch of novel products
  • Novel diagnostic tools increase patient population
Part 11: Impact of drivers

Part 12: Market challenges
  • Continuous change in guidelines from healthcare organizations impacts market growth
  • Cyclical nature of market hinders growth opportunities
  • Limited drugs in market leading to low penetration rates
Part 13: Impact of drivers and challenges

Part 14: Market trends
  • Emergence of new entrants likely to change market dynamics
  • Growing strategic collaborations fostering innovation
  • Active Participation from emerging economies toward R&D
Part 15: Vendor landscape
  • Competitive scenario
Part 16: Key vendor analysis
  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical
  • Other prominent vendors
Part 17: Appendix
  • List of abbreviations
Part 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global human respiratory syncytial virus drugs market
Exhibit 03: Snapshot of RSV infection
Exhibit 04: Key buying criteria for RSV drugs
Exhibit 05: Factors affecting the adoption rates of RSV drugs
Exhibit 06: Pipeline analysis of key vendors in global human respiratory syncytial virus drugs market
Exhibit 07: Percentage share of drug candidates by stage of development
Exhibit 08: Pipeline candidates: Global human respiratory syncytial virus drugs market
Exhibit 09: Global human respiratory syncytial virus drugs market snapshot
Exhibit 10: Analysis of global human respiratory syncytial drugs market
Exhibit 11: Global human respiratory syncytial virus drugs market 2015-2020 ($ billions)
Exhibit 12: Emerging vendors and their initiatives
Exhibit 13: Opportunity analysis of global respiratory syncytial virus drugs market
Exhibit 14: Opportunity analysis in developed and emerging markets
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of global human respiratory syncytial virus drugs market by type of drug 2015
Exhibit 17: Segmentation of global human respiratory syncytial virus drugs market based on geography 2015 and 2020
Exhibit 18: Global human respiratory syncytial virus drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 19: Incidence of RSV infections in US (on average every year)
Exhibit 20: Global human respiratory syncytial virus drugs market in US 2015-2020 ($ millions)
Exhibit 21: Key drivers and challenges in US
Exhibit 22: Human respiratory syncytial virus drugs market in Europe 2015-2020 ($ millions)
Exhibit 23: Trends in global human respiratory syncytial drugs market in Europe
Exhibit 24: Global human respiratory syncytial virus drugs market in ROW 2015-2020 ($ millions)
Exhibit 25: Key drivers and challenges in ROW
Exhibit 26: Trends in RSV epidemics
Exhibit 27: Potential products
Exhibit 28: Impact of drivers
Exhibit 29: Change in guidelines of AAPCID and its consequences
Exhibit 30: Impact of cyclical nature of RSV epidemics
Exhibit 31: Factors affecting penetration rates
Exhibit 32: Forcefield analysis of drivers and challenges in global human respiratory syncytial virus drugs market
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Potential entrants
Exhibit 35: Strategic alliances
Exhibit 36: Competitive structure analysis of global human respiratory syncytial virus drugs market 2015
Exhibit 37: Market share analysis 2015
Exhibit 38: Market penetration of various RSV drug manufacturers in global human respiratory syncytial virus drugs market (2015)
Exhibit 39: Strategic success factors of companies in global human respiratory syncytial virus drugs market
Exhibit 40: AstraZeneca: Key highlights
Exhibit 41: AstraZeneca: Strength assessment
Exhibit 42: AstraZeneca: Strategy assessment
Exhibit 43: AstraZeneca: Opportunity assessment
Exhibit 44: AstraZeneca: Revenue of Synagis 2013-2015 ($ billions)
Exhibit 45: AstraZeneca: Geographic segmentation of Synagis 2015
Exhibit 46: AbbVie: Strength assessment
Exhibit 47: AbbVie: Strategy assessment
Exhibit 48: AbbVie: Opportunity assessment
Exhibit 49: AbbVie: Revenue of Synagis 2013-2015 ($ millions)
Exhibit 50: GSK: Profile
Exhibit 51: GSK: Strength assessment
Exhibit 52: GSK: Strategy assessment
Exhibit 53: GSK: Opportunity assessment
Exhibit 54: GSK: Revenue of Ventolin 2013-2015 ($ billions)
Exhibit 55: GSK: Geographical segmentation of Ventolin 2015
Exhibit 56: Teva Pharmaceutical: Profile
Exhibit 57: Teva Pharmaceutical: Strength assessment
Exhibit 58: Teva Pharmaceutical strategy assessment
Exhibit 59: Teva Pharmaceutical: Opportunity assessment
Exhibit 60: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Alnylam Pharmaceuticals
  • Aviragen Therapeutics
  • Gilead Sciences
  • Kyowa Hakko Kirin
  • Mymetics Corporation
  • MORE
Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Key players in the global human respiratory syncytial virus drugs market: AstraZeneca, AbbVie, GSK, and Teva Pharmaceutical.

Other Prominent Vendors in the market are: Ablynx, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, Aviragen Therapeutics, Bavarian Nordic, Boehringer Ingelheim, Gilead Sciences, ImmunoVaccine Technologies, Johnson & Johnson, Kyowa Hakko Kirin, Medivir, Mucosis, Mymetics, Novavax, Regeneron Pharmaceuticals, ReViral, and Vaxart.

Commenting on the report, an analyst from the team said: “One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period. For instance, in January 2016, Mucosis received $4.1 million funding from the Wellcome Trust, a global charitable foundation focusing on improving health, to advance SynGEM, its proprietary intranasal RSV vaccine, into phase I and IIa human clinical trials. In September 2015, OrbiMed and Edmond de Rothschild Investment Partners co-led a $21 million series A round in ReViral, a London-based company that is developing RV521, a drug for the treatment of RSV. In June 2015, Immunovaccine commenced phase I clinical study of its DPX-RSV vaccine. The vaccine candidate contains a specific target and a viral protein that is active on the surface of infected cells. It is believed that an immune response to the specific target will limit the severity of RSV infection. The entry of new companies will certainly pave the way for the development of novel products for the treatment of RSV.”

According to the report, one driver in the market is presence of large patient pool fuels market growth. RSV is the leading cause of lower respiratory tract infections in infants and young children. Each year, 4-5 million children younger than four years of age acquire an RSV infection, and more than 0.12 million are hospitalized annually in the US because of this infection. For example, approximately 25 to 40 out of 100 individuals with RSV have signs or symptoms of pneumonia or bronchiolitis. Five to 20 out of 1,000 require hospitalization. Also, adults with compromised immune systems and of ages 65 and older are also at a higher risk of severe disease. In the US, on average, RSV leads to 57,257 hospitalizations among children of ages below 5 years; 2.1 million outpatient visits among children less than 5 years; and 0.17 million hospitalizations and 14,000 death cases among adults of ages more than 65 years. The presence of this large RSV patient pool with highly unmet medical needs with single approved therapy is expected to drive the market growth during the forecast period.

Further, the report states that one challenge in the market is continuous change in guidelines from healthcare organizations impacts market growth. The dynamic nature of guidelines from the American Academy of Pediatrics Committee on Infectious Disease (AAPCID) restricted the patients eligible for preventive treatment with Synagis, the leading drug in the market. Synagis received US FDA approval in June 1998 for the treatment of lower respiratory infection caused by RSV. Since then, the AAPCID updated its guidance related to Synagis four times. The recent update (2014) states that the use of Synagis prophylaxis in infants and children should be restricted to those that are at increased risk of RSV infection. Earlier, the definition of high-risk children on the Synagis package was not included. Most payers in the US have implemented these guidelines in 2014.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Ablynx
  • ADMA Biologics
  • Alnylam Pharmaceuticals
  • Ark Biosciences
  • AstraZeneca
  • Aviragen Therapeutics
  • Bavarian Nordic
  • Boehringer Ingelheim
  • Gilead Sciences
  • GSK
  • ImmunoVaccine Technologies
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Medivir
  • Mucosis
  • Mymetics Corporation
  • Novavax
  • Regeneron Pharmaceuticals
  • ReViral
  • Teva Pharmaceutical
  • Vaxart
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll